The global colistin market is driven by antimicrobial resistance and the limited availability of effective treatments for severe Gram-negative infections. Intravenous, inhaled, and topical forms serve patients with ventilator-associated pneumonia, bloodstream infections, and urinary tract infections. Tighter controls on livestock use are shifting the market toward human healthcare. Kidney and nerve toxicity remain key clinical drawbacks.

According to The Insight Partners, the Colistin Market size is projected to reach US$ 510.94 million by 2034 from US$ 337.00 million in 2025. The market is expected to register a CAGR of 4.8% during 2026–2034.

Colistin Market Overview

The colistin market is gaining attention due to the growing challenge of antimicrobial resistance and the need for effective treatment options against certain multidrug-resistant bacterial infections. Colistin, also known as polymyxin E, is an antibiotic primarily used to treat serious infections caused by susceptible Gram-negative bacteria, including certain strains of Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. It is generally reserved for infections where alternative treatment options are limited because of its potential for serious adverse effects, particularly kidney toxicity.

Download Sample PDF - https://www.theinsightpartners.com/sample/TIPRE00042707

Colistin is available in different formulations, including colistimethate sodium for intravenous administration and other preparations used in specific clinical settings. Its role in treating difficult-to-manage infections has sustained demand among hospitals and healthcare institutions. However, its use requires careful clinical assessment, appropriate dosing, and monitoring to manage potential toxicity and limit the development of further antimicrobial resistance.

The market is influenced by hospital-acquired infection rates, antimicrobial resistance patterns, pharmaceutical manufacturing capabilities, and regulatory policies governing antibiotic use. Pharmaceutical companies are also focusing on product quality, formulation development, and reliable supply chains to support access to colistin-based medicines.

Key Players in the Colistin Market

• TZF Polfa S.A.
• Tecoland Corporation
• Fujian Lifecome Biochemistry Limited
• Zhejiang Shenghua Biok Chemical Company Limited
• Xellia Pharmaceuticals ApS
• Shandong LuKang Pharmaceutical Co. Ltd.
• Livzon Pharmaceutical Group Inc.
• Apeloa Pharmaceutical Co. Ltd.
• Norma Hellas S.A.
• Hebei Shengxue Dacheng Pharmaceutical Co. Ltd.

Market Drivers and Trends

Increasing Antimicrobial Resistance: The growing prevalence of antimicrobial-resistant Gram-negative bacterial infections is an important factor influencing the colistin market. Some infections caused by organisms such as Acinetobacter and Pseudomonas can be difficult to treat because of resistance to multiple antibiotic classes. Colistin may be considered in selected severe cases when other effective treatment options are limited, supporting its continued clinical relevance.

Rising Hospital-Acquired Infections: Healthcare-associated infections remain a concern for hospitals, particularly among patients in intensive care units and those requiring invasive medical procedures. Patients with weakened immune systems or prolonged hospital stays may be at increased risk of serious bacterial infections. The need for effective treatment options in these settings contributes to demand for reserve antibiotics such as colistin.

Demand for Critical-Care Antibiotics: The growing need for specialized infection management in intensive care and other hospital departments supports the use of antibiotics reserved for difficult-to-treat infections. Colistin is used under carefully controlled clinical conditions, with treatment decisions based on susceptibility testing, patient factors, and available alternatives.

Pharmaceutical Manufacturing Developments: Improvements in pharmaceutical production, quality control, and formulation processes are important for maintaining the availability and consistency of colistin products. Manufacturers are focusing on reliable production practices and compliance with regulatory quality standards.

Antimicrobial Stewardship Initiatives: Healthcare organizations are strengthening antimicrobial stewardship programs to promote appropriate antibiotic selection, dosing, and duration of treatment. Although these initiatives encourage restricted and responsible colistin use, they also reinforce the importance of maintaining access to effective reserve antibiotics for eligible patients.

Colistin Market Size, Share, Trends, Analysis, and Forecast by 2034

• Market Size: The global colistin market is projected to reach US$ 510.94 million by 2034, increasing from US$ 337.00 million in 2025.
• Market Growth: The market is expected to register a CAGR of 4.8% during 2026–2034, supported by continued demand for treatments targeting selected multidrug-resistant infections.
• Key Market Trend: Increasing attention to antimicrobial resistance and hospital infection management is shaping demand for reserve antibiotics.
• Major Growth Driver: The prevalence of difficult-to-treat Gram-negative bacterial infections is supporting the clinical relevance of colistin.
• Product Development: Improvements in pharmaceutical manufacturing, formulation quality, and supply chain management are influencing market development.
• Future Opportunities: Continued research into antimicrobial resistance and infection management may create opportunities for pharmaceutical manufacturers through 2034.

Regional Analysis

North America: North America represents an important market due to advanced healthcare infrastructure, established pharmaceutical industries, and growing focus on antimicrobial resistance. Hospital infection management and access to specialized antibiotic treatments influence regional demand.

United States: The US market is supported by advanced hospital facilities, antimicrobial resistance surveillance, and pharmaceutical research. Colistin remains a reserve treatment option for selected serious infections caused by susceptible multidrug-resistant Gram-negative bacteria.

Europe: Europe is an established pharmaceutical market with strong regulatory frameworks and antimicrobial stewardship initiatives. Continued monitoring of resistant bacterial infections and demand for specialized hospital antibiotics influence market development.

Asia Pacific: Asia Pacific presents growth opportunities due to its large patient population, expanding healthcare infrastructure, and continuing challenges associated with antimicrobial resistance. Pharmaceutical manufacturing capabilities in countries such as China and India also contribute to the regional supply landscape.

South and Central America: Market development in South and Central America is influenced by improvements in hospital infrastructure, access to essential antibiotics, and efforts to address drug-resistant infections. Healthcare investment and pharmaceutical distribution networks may support future demand.

Middle East and Africa: The Middle East and Africa market is shaped by expanding healthcare services, hospital infection management requirements, and increasing attention to antimicrobial resistance. Improvements in access to essential medicines and diagnostic facilities may influence future market growth.

Future Outlook

The colistin market is expected to experience moderate growth through 2034, supported by the continuing need for treatment options against selected multidrug-resistant bacterial infections. Increasing antimicrobial resistance, hospital-acquired infections, and demand for specialized critical-care antibiotics will remain important market factors. At the same time, responsible antibiotic use and antimicrobial stewardship will influence prescribing practices. Pharmaceutical manufacturers are expected to focus on product quality, reliable supply, and regulatory compliance. Continued research into resistance patterns and alternative treatment approaches will also shape the market's long-term development.

About Us

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us

Ankit Mathur | The Insight Partners
Email: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876